Alexion Pharmaceuticals:

"Best Practices for Approaching Strategic Partners"

& One-on-One Meetings!

Get answers directly from a global player in the pharmaceutical industry:

• Do’s and don’ts of approaching strategic partners
• What to present
• How to effectively negotiate 

There will be an opportunity for OBIO Members to meet with Andrew after the presentation. Interested companies should message jordancork@obio.ca by Friday September 15th (OBIO Members Only).

Make sure to attend in person, by GoToMeeting, or teleconference, and have your questions ready! 

Alexion is a global biopharmaceutical company focused on developing and delivering life-changing therapies for patients with devastating and rare diseases. Patients with these life-threatening diseases often have no effective treatment options, and they and their families suffer with little hope. Our goal is to deliver medical breakthroughs where none currently exist.

Andrew Hutchinson is an External Research & Scouting Lead at Alexion Pharmaceuticals and is focused on the search, identification and evaluation of business development opportunities. He has a diverse background in biotech start-ups, large biotech and academia, and has led programs in biologics, small molecules and peptide therapeutics. From 2014 to 2015, Andrew was an Assistant Professor and Fulbright Scholar at Yale, and from 2010 to 2014, he was a lecturer of biotechnology at the University of Technology Sydney (Australia) where he co-founded the start-up companies Helmedix and QUE Oncology. Prior to this, Andrew was a scientist at Immune System Therapeutics where he developed a mAb therapy that is currently being assessed in the clinic for multiple myeloma. Andrew obtained his PhD at the University of Technology Sydney, and also holds separate Bachelors’ degrees in Science and Finance from the University of Sydney.